Skip to main content

Table 1 Baseline characteristics of 82 patients diagnosed with IC in the ICU

From: Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: a retrospective study from 2011 to 2017 in a teaching hospital in China

 

N (%) or P50 (P25,P75)

Mortality status (all-cause)

Survived (n = 40)

Did not survive (n = 42)

Z/χ2/ Fisher’s exact test

P

Age (years)

76.0 (65.8, 82.0)

76.0 (61.3, 81.8)

78.0 (67.0, 84.0)

−0.673#

0.501

Males

50 (61.0)

26 (65.0)

24 (57.1)

0.532*

0.466

Hospital admission

 Medical ward

28 (34.1)

14 (35.0)

14 (33.3)

0.025*

0.874

 Surgical ward

54 (65.9)

26 (65.0)

28 (66.7)

  

Underlying conditions

 Diabetes

27 (32.9)

12 (30.0)

15 (35.7)

0.303*

0.582

 Hypertension

36 (43.9)

14 (35.0)

22 (52.4)

2.513*

0.113

 Chronic cardiac disease

18 (22.0)

7 (17.5)

11 (26.2)

0.903*

0.342

 Chronic liver disease

9 (11.0)

5 (12.5)

4 (9.5)

0.006*

0.938

 Solid tumor

30 (36.6)

15 (37.5)

15 (35.7)

0.028*

0.867

 COPD

2 (2.4)

0 (0.0)

2 (4.8)

-Δ

0.494

 Hematological malignancy

5 (6.1)

2 (5.0)

3 (7.1)

0.000*

1.000

 Chronic renal dysfunction

17 (20.7)

4 (10.0)

13 (31.0)

5.473*

0.019

 Surgery

48 (58.5)

25 (62.5)

23 (54.8)

0.505*

0.477

GCS score

11.0 (9.0, 15.0)

11.0 (11.0, 15.0)

10.0 (6.0, 11.0)

−4.225#

0.000

Previous treatment

 Antifungal treatment

27 (32.9)

12 (30.0)

15 (35.7)

0.303*

0.582

 Caspofungin

22 (26.8)

11 (27.5)

11 (26.2)

0.018*

0.894

 Fluconazole

39 (47.6)

19 (47.5)

20 (47.6)

0.000*

0.991

 Amphotericin B

2 (2.4)

0 (0.0)

2 (4.8)

-Δ

0.494

 Voriconazole

32 (39.0)

18 (45.0)

14 (33.3)

1.172*

0.279

 Previous steroid therapy

25 (30.5)

10 (25.0)

15 (35.7)

1.110*

0.292

 Previous antibiotic therapy

63 (76.8)

31 (77.5)

32 (76.2)

0.020*

0.888

Laboratory data

 P/F ratio

256.1 (188.4, 337.3)

290.5 (241.5, 370.8)

224.0 (130.0, 270.0)

−3.553#

0.000

 Anemia (HGB < 70 g/l)

27 (32.9)

10 (25.0)

17 (40.5)

2.222*

0.136

 Neutropenia (< 1 months)

7 (8.5)

2 (5.0)

5 (11.9)

0.523*

0.470

 WBC > 20*109/l

26 (31.7)

11 (27.5)

15 (35.7)

0.638*

0.424

 Temperature > 38 °C

68 (82.9)

31 (77.5)

37 (88.1)

1.624*

0.202

 Hypoproteinemia

81 (98.8)

39 (97.5)

42 (100.0)

-Δ

0.488

 MAP, mean (SD)

76.7 (66.5, 90.0)

85.5 (73.3, 94.5)

68.0 (57.0, 78.3)

−4.134#

0.000

Previous invasive procedures

 Central venous catheter

13.0 (5.5, 27.0)

13.0 (6.0, 25.5)

14.0 (4.5, 29.5)

−0.454#

0.650

 Urinary tract catheter

13.0 (5.0, 27.0)

12.5 (5.0, 24.0)

17.0 (5.5, 35.5)

−1.026#

0.305

 Total parenteral nutrition

10.5 (3.8, 21.3)

8.5 (3.3, 15.8)

13.0 (4.5, 27)

−1.023#

0.307

 Mechanical ventilation

3.5 (1.0, 10.3)

2.5 (1.0, 9.5)

5.50 (1.0, 15.0)

−1.514#

0.130

SOFA score

8.0 (4.0, 11.0)

5.0 (4.0, 8.0)

10.0 (8.5, 14.0)

−4.628#

0.000

Outcome (days)

 ICU length of stay

16.0 (4.8, 51.8)

16.0 (5.3, 36.3)

14.5 (3.0, 66.0)

−0.223#

0.823

 Hospital length of stay

45.0 (27.8, 81.3)

40.0 (28.0, 98.0)

49.0 (26.5, 81.0)

−0.014#

0.989

 Mechanical ventilation

8.5 (1.8, 23.3)

5.0 (1.0, 11.0)

11.5 (3.0, 37.5)

−2.461#

0.014

  1. *: Chi-square test; #: rank sum test; Δ: Fisher’s exact test
  2. P50 (P25,P75): the quartile summary is viewed as P25, P50, and P75. For P50, there is a 50% chance that the mean power production will not be reached at any given time